Screening test results associated with cancer diagnoses in 287 women with cervical squamous cell carcinoma

Archives of Pathology and Laboratory Medicine

Volumn 136, Issue 12, 2012, Pages 1533-1540

  Li, Zaibo ^a   Austin, R Marshall ^a   Guo, Ming ^b   Zhao, Chengquan ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALPHAPAPILLOMAVIRUS; CANCER INVASION; CONFERENCE PAPER; EARLY DIAGNOSIS; ELECTRONIC MEDICAL RECORD; EVALUATION; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; ISOLATION AND PURIFICATION; METHODOLOGY; MIDDLE AGED; PAPILLOMAVIRUS INFECTION; PATHOLOGY; RETROSPECTIVE STUDY; RISK; SQUAMOUS CELL CARCINOMA; UNITED STATES; UNIVERSITY HOSPITAL; UTERINE CERVIX; UTERINE CERVIX TUMOR; VAGINA SMEAR; VIROLOGY;

ACADEMIC MEDICAL CENTERS; ADULT; AGED; AGED, 80 AND OVER; ALPHAPAPILLOMAVIRUS; CARCINOMA, SQUAMOUS CELL; CERVIX UTERI; EARLY DETECTION OF CANCER; ELECTRONIC HEALTH RECORDS; FEMALE; FOLLOW-UP STUDIES; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; PAPILLOMAVIRUS INFECTIONS; PENNSYLVANIA; RETROSPECTIVE STUDIES; RISK; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 84869210546     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2011-0609-OA     Document Type: Conference Paper

References (93)

1. Koss L. The Papanicolaou test for cervical cancer detection: a triumph and a tragedy. JAMA. 1989;261(5):737-743.
2. Gustafsson L., Ponte'n J, Zack M, Adami HO. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control. 1997;8(5):755-763.
3. Lee KR, Ashfaq R, Birdson GG, Corkill ME, McIntosh KM, Inhorn SL. Comparison of conventional Papanicolaou smears and a fluid-based, thin-layer system for cervical cancer screening. Obstet Gynecol. 1997;90(2):278-284.
4. Marino JF, Fremont-Smith M. Direct-to-vial experience with AutoCyte PREP in a small New England regional cytology practice. J Reprod Med. 2001;46(4): 353-358.
5. Davey E, d'Assuncao J, Irwig L, et al. Accuracy of reading liquid based cytology slides using the ThinPrep Imager compared with conventional cytology: prospective study. BMJ. 2007;335(7609):31.
6. Wilbur DC, Black-Schaffer WS, Luff RD, et al. The Becton Dickinson FocalPoint GS Imaging System: clinical trials demonstrate significantly improved sensitivity for the detection of important cervical lesions. Am J Clin Pathol. 2009; 132(5):767-775.
7. Solomon D, Schiffman M, Tarone R; ALTS Study Group. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst. 2001;93(4):293-299.
8. Einstein MH, Martens MG, Garcia FA, et al. Clinical validation of the Cervista HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology. Gynecol Oncol. 2010;118(2):116-122.
9. Wright TC, Schiffman M. Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl J Med. 2003;348(6):489-490.
10. Wright TC Jr, Schiffman M, Solomon D, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol. 2004;103(2):304-309.
11. Sawaya GF. Rightsizing cervical cancer screening: comment on "Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone." Arch Intern Med. 2010;170(11):985-986.
12. Kitchener HC, Blanks R, Cubie H, et al. MAVARIC-a comparison of automation-assisted and manual cervical screening: a randomised controlled trial. Health Technol Assess. 2011;15(3):iii-iv, ix-Xi, 1-170.
13. Abulafia O, Pezzullo JC, Sherer DM. Performance of ThinPrep liquidbased cervical cytology in comparison with conventionally prepared Papanicolaou smears: a quantitative survey. Gynecol Oncol. 2003;90(1):137-144.
14. Bernstein SJ, Sanchez-Ramos L, Ndubisi B. Liquid-based cervical cytologic smear study and conventional Papanicolaou smears: a metaanalysis of prospective studies comparing cytologic diagnosis and sample adequacy. Am J Obstet Gynecol. 2001;185(2):308-317.
15. Nance KV. Evolution of Pap testing at a community hospital-a ten year experience. Diagn Cytopathol. 2007;35(3):148-153.
16. Ronco G, Cuzick J, Pierotti P, et al. Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial. BMJ. 2007;335(7609):28.
17. Siebers AG, Klinkhamer PJ, Grefte JM, et al. Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial. JAMA. 2009;302(16):1757-1764.
18. Saraiya M, Berkowitz Z, Yabroff KR, Wideroff L, Kobrin S, Benard V. Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending? Arch Intern Med 2010;170(11):977-985.
19. Lee JW, Berkowitz Z, Saraiya M. Low-risk human papillomavirus testing and other nonrecommended human papillomavirus testing practices among US health care providers. Obstet Gynecol. 2011;118(1):4-13.
20. Hing E, Saraiya M, Roland KB. Liquid-based cytology test use by officebased physicians: United States, 2006-2007. Natl Health Stat Report. 2011;(40): 1-6.
21. Benard VB, Saraiya MS, Soman A, Roland KB, Yabroff KR, Miller J. Breast and cervical cancer screening practices among physicians in the national breast and cervical cancer early detection program. J Womens Health (Larchmt). 2011; 20(10):1479-1484.
22. Smith HO, Benwick M, Qualls CF, Verschraegen CF, Wiggins C. 30 Year trends in cervical cancer incidence rates: a surveillance, epidemiology, and end results program population-based study. In: Proceedings from the Society of Gynecologic Oncologists; March 4-7, 2007; San Diego, CA. Abstract 196.
23. Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinomas relative to squamous cell carcinoma of the uterine cervix in the United States-A 24-year population-based study. Gynecol Oncol. 2000;78(2): 97-105.
24. Sigurdsson K, Hrafnkelsson J, Geirsson G, Gudmundsson J, Salvarsdó ttir A. Screening as a prognostic factor in cervical cancer: analysis of survival and prognostic factors based on Icelandic population data, 1964-1988. Gynecol Oncol. 1991;43(1):64-70.
25. Sung HY, Kearney KA, Miller M, Kinney W, Sawaya GF, Hiatt RA. Papanicolaou smear history and diagnosis of invasive cervical carcinoma among members of a large prepaid health plan. Cancer. 2000;88(10):2283-2289.
26. Andrae B, Kemetli L, Spare'n P, et al. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst. 2008;100(9):622-629.
27. Sasieni PD, Cuzick J, Lynch-Farmery E; National Co-ordinating Network for Cervical Screening Working Group. Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. Br J Cancer. 1996;73(8):1001-1005.
28. Herbert A, Anshu, Gregory M, Gupta SS, Singh N. Invasive cervical cancer audit: a relative increase in interval cancers while coverage increased and incidence declined. BJOG. 2009;116(6):845-853.
29. Austin RM, Onisko A, Druzdel M. The Pittsburgh cervical cancer screening model: a risk assessment tool. Arch Pathol Lab Med. 2010;134(5): 744-750.
30. Zhao C, Austin RM. Human papillomavirus DNA detection in ThinPrep Pap test vials is independent of cytologic sampling of the transformation zone. Gynecol Oncol. 2007;107(2):231-235.
31. Zhao C, Austin RM. Adjunctive high-risk human papillomavirus DNA testing is a useful option for disease risk assessment in patients with negative Papanicolaou tests without an endocervical/transformation zone sample. Cancer. 2008;114(4):242-248.
32. Zhao C, Florea A, Onisko A, Austin RM. Histologic follow-up results in 662 patients with Pap test findings of atypical glandular cells: results from a large academic womens hospital laboratory employing sensitive screening methods. Gynecol Oncol. 2009;114(3):383-389.
33. Zhao C, Florea A, Austin RM. Clinical utility of adjunctive high risk HPV DNA testing in women with pap test findings of atypical glandular cells. Arch Pathol Lab Med. 2010;134(1):103-108.
34. Bandyopadhyay S, Austin RM, Dabbs D, Zhao C. Adjunctive human papillomavirus DNA testing is a useful option in some clinical settings for disease risk assessment and triage of females with ASC-H Papanicolaou test results. Arch Pathol Lab Med. 2008;132(12):1874-1881.
35. Armah H, Austin RM, Dabbs D, Zhao C. Follow-up findings for women with human papillomavirus-positive and atypical squamous cells of undetermined significance screening test results in a large women's hospital practice. Arch Pathol Lab Med. 2009;133(9):1426-1430.
36. Zhao C, Elishaev E, Yuan KH, Yu J, Austin RM. Very low human papillomavirus DNA prevalence in mature women with negative computerimaged liquid-based Pap tests. Cancer. 2007;111(5):292-297.
37. Bansal M, Austin RM, Zhao C. High-risk HPV DNA detected in less than 2% of over 25,000 cytology negative imaged liquid-based Pap test samples from women 30 and older. Gynecol Oncol. 2009;115(2):257-261.
38. Zhao C, Zhao S, Heider A, Austin RM. Significance of high risk HPV DNA detection in women 50 and older with squamous cell pap test abnormalities. Arch Pathol Lab Med. 2010;134(8):1130-1135.
39. Heider A, Austin RM, Zhao C. HPV test results stratify risk for histopathologic follow-up findings of high-grade cervical intra-epithelial neoplasia in women with low-grade squamous intra-epithelial lesion Pap results. Acta Cytol. 2011;55(1):48-53.
40. Zhao C, Kalposi-Novak P, Austin RM. Follow-up findings in adolescents with HSIL Pap test results. Arch Pathol Lab Med. 2011;135(3):361-364.
41. Zhao C, Chen X, Onisko A, Kanbour A, Austin RM. Follow-up outcomes for a large cohort of US women with negative imaged liquid-based cytology findings and positive high risk human papillomavirus test results. Gynecol Oncol. 2011;122(2):291-296.
42. Gao FF, Austin RM, Zhao C. Histopathologic follow-up and human papillomavirus DNA test results in 290 patients with high-grade squamous intraepithelial lesion Papanicolaou test results. Cancer Cytopathol. 2011;119(6): 377-386.
43. Clavel C, Masure M, Putaud I, et al. Hybrid capture II, a new sensitive test for human papillomavirus detection: comparison with hybrid capture I and PCR results in cervical lesions. J Clin Pathol. 1998;51(10):737-740.
44. Guo M, Gong Y, Deavers M, et al. Evaluation of a commercialized in situ hybridization assay for detecting human papillomavirus DNA in tissue specimens from patients with cervical intraepithelial neoplasia and cervical carcinoma. J Clin Microbiol. 2008;46(1):274-280.
45. Lin, CY, Chen HC, Lin RW, et al. Quality assurance of genotyping array for detection and typing of human papillomavirus. J Virol Methods. 2007;140(1-2): 1-9.
46. Subramaniam A, Fauci JM, Schneider KE, et al. Invasive cervical cancer and screening: what are the rates of unscreened and underscreened women in the modern era? J Low Genit Tract Dis. 2011;15(2):110-113.
47. Kirschner B, Poll S, Rygaard C, Wa°hlin A, Junge J. Screening history in women with cervical cancer in a Danish population-based screening program. Gynecol Oncol. 2011;120(1):68-72.
48. Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011;12(7): 663-672.
49. Herbert A, Anshu, Culora G, et al. Invasive cervical cancer audit: why cancers developed in a high-risk population with an organised screening programme. BJOG. 2010;117(6):736-745.
50. Herbert A, Anshu, Gregory M, Gupta SS, Singh N. Screen-detected invasive cervical carcinoma and its clinical significance during the introduction of organized screening. BJOG. 2009;116(6):854-859.
51. Hoyer H, Scheungraber C, Kuehne-Heid R, et al. Cumulative 5-year diagnoses of CIN2, CIN3 or cervical cancer after concurrent high-risk HPV and cytology testing in a primary screening setting. Int J Cancer. 2005;116(1):136- 143.
52. Nyga°rd JF, Nyga°rd M, Skare GB, Thoresen SØ. Screening histories of women with CIN 2/3 compared with women diagnosed with invasive cervical cancer: a retrospective analysis of the Norwegian Coordinated Cervical Cancer Screening Program. Cancer Causes Control. 2005;16(4):463-474.
53. Herbert A, Singh N, Smith JA. Adenocarcinoma of the uterine cervix compared with squamous cell carcinoma: a 12-year study in Southampton and South-west Hampshire. Cytopathology. 2001;12(1):26-36.
54. Wallin KL, Wiklund F, Angström T, et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med. 1999;341(22):1633-1638.
55. Kenter GG, Schoonderwald EM, Koelma IA, Arentz N, Hermans J, Fleuren GJ. The cytological screening history of 469 patients with squamous cell carcinoma of the cervix uteri; does interval carcinoma exist? Acta Obstet Gynecol Scand. 1996;75(4):400-403.
56. Janerich DT, Hadjimichael O, Schwartz PE, et al. The screening histories of women with invasive cervical cancer, Connecticut. Am J Public Health. 1995; 85(6):791-794.
57. Slater DN, Milner PC, Radley H. Audit of deaths from cervical cancer: Proposal for an essential component of the National Screening Programme. J Clin Pathol. 1994;47(1):27-28.
58. Anderson GH, Benedet JL, Le Riche JC, Matisic JP, Thompson JE. Invasive cancer of the cervix in British Columbia: a review of the demography and screening histories of 437 cases seen from 1985-1988. Obstet Gynecol. 1992; 80(1):1-4.
59. Nasca PC, Ellish N, Caputo TA, Saboda K, Metzger B. An epidemiologic study of Pap screening histories in women with invasive carcinomas of the uterine cervix. N Y State J Med. 1991;91(4):152-156.
60. Carmichael JA, Jeffrey JF, Steele HD, Ohlke ID. The cytologic history of 245 patients developing invasive cervical carcinoma. Am J Obstet Gynecol. 1984;148(5):685-690.
61. Laskey PW, Meigs JW, Flannery JT. Uterine cervical carcinoma in Connecticut, 1935-1973:evidence for two classes of invasive disease. J Natl Cancer Inst. 1976;57(5):1037-1043.
62. Martin PL. How preventable is invasive cervical cancer?: a community study of preventable factors. Am J Obstet Gynecol. 1972;113(4):541-548.
63. Sawaya GF, Sung HY, Kearney KA, et al. Advancing age and cervical cancer screening and prognosis. J Am Geriatr Soc. 2001;49(11):1499-1504.
64. Vesco KK, Whitlock EP, Eder M, Lin J, et al. Screening for Cervical Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality; 2011. Evidence synthesis 86. AHRQ publication 11-05156-EF-1.
65. Linder J, Keene J, Sheets E. Cervical cancer reduction through higher sensitivity Pap testing: observed versus calculated effects. Cancer Cytopathol. 2007;111(suppl 5):369.
66. Swan, D C. Tucker RA, Tortolero-Luna G, et al. Human papillomavirus (HPV) DNA copy number is dependent on grade of cervical disease and HPV type. J Clin Microbiol. 1999;37(4):1030-1034.
67. Gravitt PE, Burk RD, Lorincz A, et al. A comparison between real-time polymerase chain reaction and hybrid capture 2 for human papillomavirus DNA quantitation. Cancer Epidemiol Biomarkers Prev. 2003;12(6):477-484.
68. Ho, CM. Yang SS, Chien TY, Huang SH, Jeng CJ, Chang SF. Detection and quantitation of human papillomavirus type 16, 18, and 52 DNA in the peripheral blood of cervical cancer patients. Gynecol Oncol. 2005;99(3): 615-621.
69. Woodman, CB, Collins S, Rollason TP, et al. Human papillomavirus type 18 and rapidly progressing cervical intraepithelial neoplasia. Lancet. 2003; 361(9351):40-43.
70. Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer. 2007;7(1):11-22.
71. Peevor R, Bowden S, Jones J, Fiander AN, Hibbitts S. Human Papillomavirus negative but dyskaryotic cervical cytology: re-analysis of molecular testing. J Clin Virol. 2009;44(4):322-324.
72. Kinney W, Fetterman B, Cox T, Lorey T, Flanagan T, Castle PE. Characteristics of 44 cervical cancers diagnosed following Pap negative HPV positive screening in routine clinical practice. Gynecol Oncol. 2011;121(2):309-313.
73. Cuzick J, Clavel C, Petry KU, et al. Overview of North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119(5): 1095-1101.
74. Koliopoulos G, Arbyn M, Martin-Hirsch P, Kyrgiou M, Prendiville W, Paraskevaidis E. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol Oncol. 2007;104(1):232-246.
75. Lynge E, Rebolj M. Primary HPV screening for cervical cancer prevention: results from European trials. Nat Rev Clin Oncol. 2009;6(12):699-706.
76. Rebolj M, Lynge E. Has cytology become obsolete as a primary test in screening for cervical cancer? J Med Screen. 2010;17(1):1-3.
77. Kitchener HC, Almonte M, Thomson C, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol. 2009;10(7):672-682.
78. Kitchener HC, Gilham C, Sargent A, et al. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. Eur J Cancer. 2011;47(6):864- 871.
79. Castle PE, Schiffman M, Wheeler C, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol. 2009; 113(1):18-25.
80. Carreon JD, Sherman ME, Guillen D, et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol. 2007;26(4): 441-446.
81. McCredie MR, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008;9(5):425-434.
82. Sycuro LK, Xi LF, Hughes JP, et al. Persistence of genital human papillomavirus infection in a long-term follow-up study of female university students. J Infect Dis. 2008;198(7):971-978.
83. Rodri'guez AC, Schiffman M, Herrero R, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst. 2008;100(7):513-517.
84. Rodri'guez AC, Schiffman M, Herrero R, et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst. 2010;102(5):315-324.
85. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12- 19.
86. Simon K, Kondratavich MV, Hojvat S, Gutierrez A. Patient safety and the next generation of HPV tests. Am J Clin Pathol. 2011;135(5):798-799.
87. Kitchener HC, Almonte M, Gilham C, et al. ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess. 2009;13(51):1-150, iii-iv.
88. Anekella B, Dryga SA, Moskowitz KA, et al. Stability of integrated HPV 16 DNA in various sample transport media. J Mol Diagn. 2007;9(5):679-680. ID37
89. Powell N, Smith K, Fiander A. Recovery of human papillomavirus nucleic acids from liquid-based cytology media. J Virol Methods. 2006;137(1):58-62.
90. Ko V, Tambouret RH, Kuebler DL, Black-Schaffer WS, Wilbur DC. Human papillomavirus testing using hybrid capture II with SurePath collection: initial evaluation and longitudinal data provide clinical validation for this method. Cancer. 2006;108(6):468-474.
91. Halling KC, Schrijver I, Persons DL. Test validation and verification for molecular diagnostic assays. Arch Pathol Lab Med. 2012;136(1):11-13.
92. Farnsworth A. Screening for the prevention of cervical cancer in the era of human papillomavirus vaccination: an Australian perspective. Acta Cytol. 2011; 55(4):307-312.
93. Austin RM, Zhao C. Observations from Pap litigation consultations. Pathol Case Rev. 2011;16(2):73-82.